Universal Therapeutics Group HIV rapid test kit wins Innovator of the Year - Health Products & Services award

Its innovation to create a fast and accessible diagnostic test kit is very timely for this issue.

Universal Therapeutics Group has earned the prestigious title of Innovator of the Year - Health Products & Services, underscoring its remarkable contribution to addressing the global health challenge posed by the human immunodeficiency virus (HIV). The company's pioneering creation, the “AwarerPRO™ HIV 1/2 Rapid Test (Oral Fluid)”, signifies a significant advancement in HIV detection technology, promising increased accessibility and efficiency in the battle against this persistent global health issue. Whilst other HIV 1/2 Rapid Test uses blood as a speciment, our innovation uses oral fluid as a speciment for the detection of HIV.

The AwarerPRO™ HIV 1/2 Rapid Test (Oral Fluid) utilises state-of-the-art colloidal gold immunochromatography assay (CGIA), a methodology rooted in the principles of enzyme-linked immunosorbent assay (ELISA) with monoclonal antibody technology and immune CG technique. These proven and widely utilised technologies are essential components of various diagnostic tests, demonstrating their effectiveness in detecting specific antibodies or antigens in biological samples.

Setting itself apart as a user-friendly and rapid testing solution, the AwarerPRO™ HIV 1/2 Rapid Test (Oral Fluid) is specifically designed for on-site detection, eliminating the need for specialised expertise or expensive equipment. The straightforward instructions guide users to swab the outer part of the gums, deposit oral fluid into the kit and await results in just 15 minutes. This simplicity makes it a versatile tool for deployment in diverse settings, including healthcare facilities, clinics, and community outreach programmes.

With an impressive accuracy rate of 99.63%, the AwarerPRO™ HIV 1/2 Rapid Test (Oral Fluid) provides a reliable and efficient method for detecting HIV antibodies, offering a crucial component for early diagnosis. Its accuracy enhances its utility as a tool for swift screening, allowing for the timely initiation of appropriate interventions.

The single-use design of the AwarerPRO™ HIV 1/2 Rapid Test (Oral Fluid) is the main feature of this Rapid Test, minimising the risk of cross-contamination and ensuring the reliability of results. This design choice underscores the commitment of Universal Therapeutics Group to maintaining the integrity and accuracy of its testing product.

The innovation showcased by Universal Therapeutics Group positions the AwarerPRO™ HIV 1/2 Rapid Test (Oral Fluid) as a powerful and accessible tool in the ongoing efforts to combat the global HIV epidemic.

AwarerPRO™ HIV 1/2 Rapid Test (Oral Fluid)- proudly Made in Malaysia.

The Malaysia Management Excellence Awards is presented by Asian Business Review Magazine. To view the full list of winners, click here. If you want to join the 2024 awards programme and be acclaimed for your company's employee engagements and management initiatives, please contact Danica Avila at [email protected].